Nadia Iovieno

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis
    Nadia Iovieno
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 1 Bowdoin Sq, Boston, MA 02114, USA
    J Clin Psychiatry 73:1300-6. 2012
  2. doi request reprint Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Nadia Iovieno
    Center for Treatment Resistant Depression, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 73:676-83. 2012
  3. doi request reprint Second-tier natural antidepressants: review and critique
    Nadia Iovieno
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Affect Disord 130:343-57. 2011
  4. doi request reprint Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
    Nadia Iovieno
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Depress Anxiety 28:137-44. 2011
  5. doi request reprint Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials
    Nadia Iovieno
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 72:1144-51. 2011
  6. doi request reprint Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis
    Paola Pedrelli
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 31:582-6. 2011
  7. doi request reprint Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials
    Nadia Iovieno
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Int Clin Psychopharmacol 26:69-74. 2011
  8. doi request reprint A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder
    Cristina Cusin
    Depression Clinical and Research Program, Massachusetts General Hospital, One Bowdoin Square, Ste 630, Boston, MA 02114
    J Clin Psychiatry 74:e636-41. 2013
  9. ncbi request reprint Folates and s-adenosylmethionine for major depressive disorder
    George I Papakostas
    Associate Professor of Psychiatry, Harvard Medical School and Director of Center for Treatment Resistant Depression, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Can J Psychiatry 57:406-13. 2012

Detail Information

Publications9

  1. doi request reprint Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis
    Nadia Iovieno
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 1 Bowdoin Sq, Boston, MA 02114, USA
    J Clin Psychiatry 73:1300-6. 2012
    ....
  2. doi request reprint Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Nadia Iovieno
    Center for Treatment Resistant Depression, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 73:676-83. 2012
    ....
  3. doi request reprint Second-tier natural antidepressants: review and critique
    Nadia Iovieno
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Affect Disord 130:343-57. 2011
    ....
  4. doi request reprint Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
    Nadia Iovieno
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Depress Anxiety 28:137-44. 2011
    ..In this study, we assess the type and frequency of residual symptoms and their relationship to subsequent depressive relapses after remission of major depression with fluoxetine...
  5. doi request reprint Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials
    Nadia Iovieno
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 72:1144-51. 2011
    ....
  6. doi request reprint Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis
    Paola Pedrelli
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 31:582-6. 2011
    ..Future studies examining the effectiveness of antidepressants while controlling for several variables such as psychosocial treatment and assessing the specific classes of antidepressants are needed...
  7. doi request reprint Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials
    Nadia Iovieno
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Int Clin Psychopharmacol 26:69-74. 2011
    ..placebo) in this population as they are in the general MDD population. Higher general response rates observed in the co-morbid MDD population are intriguing, and require replication...
  8. doi request reprint A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder
    Cristina Cusin
    Depression Clinical and Research Program, Massachusetts General Hospital, One Bowdoin Square, Ste 630, Boston, MA 02114
    J Clin Psychiatry 74:e636-41. 2013
    ..Existing augmentation or combination strategies can have substantial safety concerns that may limit their application...
  9. ncbi request reprint Folates and s-adenosylmethionine for major depressive disorder
    George I Papakostas
    Associate Professor of Psychiatry, Harvard Medical School and Director of Center for Treatment Resistant Depression, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Can J Psychiatry 57:406-13. 2012
    ..Although further randomized controlled trials in this area appear warranted, SAMe and L-methylfolate may represent a useful addition to the AD armamentarium...